SEARCH

SEARCH BY CITATION

References

  • Andreassi C., Angelozzi C., Tiziano F. D. et al. (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12, 5965.
  • Battaglia G., Princivalle A., Forti F., Lizier C. and Zeviani M. (1997) Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Hum. Mol. Genet. 6, 19611971.
  • Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F. A., Raschke H., Blumcke I., Eyupoglu I. Y. and Wirth B. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12, 24812489.
  • Chang J. G., Hsieh-Li H. M., Jong Y. J., Wang N. M., Tsai C. H. and Li H. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl Acad. Sci. USA 98, 98089813.
  • Detich N., Bovenzi V. and Szyf M. (2003) Valproate induces replication-independent active DNA demethylation. J. Biol. Chem. 278, 2758627592.
  • Eyupoglu I. Y., Hahnen E., Buslei R. et al. (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J. Neurochem. 93, 992999.
  • Germain-Desprez D., Brun T., Rochette C., Semionov A., Rouget R. and Simard L. R. (2001) The SMN genes are subject to transcriptional regulation during cellular differentiation. Gene 279, 109117.
  • Gottlicher M., Minucci S. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 69696978.
  • Haastert K., Grosskreutz J., Jaeckel M., Laderer C., Bufler J., Grothe C. and Claus P. (2005) Rat embryonic motoneurons in long-term co-culture with Schwann cells – a system to investigate motoneuron diseases on a cellular level in vitro. J. Neurosci. Methods 142, 275284.
  • Heltweg B. and Jung M. (2002) A microplate reader-based nonisotopic histone deacetylase activity assay. Anal. Biochem. 302, 175183.
  • Heltweg B., Dequiedt F., Marshall B. L., Brauch C., Yoshida M., Nishino N., Verdin E. and Jung M. (2004) Subtype selective substrates for histone deacetylases. J. Med. Chem. 47, 52355243.
  • Hockly E., Richon V. M., Woodman B. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 20412046.
  • Hu E., Dul E., Sung C. M. et al. (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720728.
  • Jung M., Brosch G., Kolle D., Scherf H., Gerhauser C. and Loidl P. (1999) Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 42, 46694679.
  • Kelly W. K., Richon V. M., O'Connor O. et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 35783588.
  • Kernochan L. E., Russo M. L., Woodling N. S., Huynh T. N., Avila A. M., Fischbeck K. H. and Sumner C. J. (2005) The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14, 11711182.
  • Kramer O. H., Zhu P., Ostendorff H. P. et al. (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22, 34113420.
  • Le T. T., Pham L. T., Butchbach M. E., Zhang H. L., Monani U. R., Coovert D. D., Gavrilina T. O., Xing L., Bassell G. J. and Burghes A. H. (2005) SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845857.
  • Lefebvre S., Burglen L., Reboullet S. et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155165.
  • Lorson C. L., Strasswimmer J., Yao J. M., Baleja J. D., Hahnen E., Wirth B., Le T., Burghes A. H. and Androphy E. J. (1998) SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 19, 6366.
  • Lorson C. L., Hahnen E., Androphy E. J. and Wirth B. (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96, 63076311.
  • Marks P. A., Richon V. M., Miller T. and Kelly W. K. (2004) Histone deacetylase inhibitors. Adv. Cancer Res. 91, 137168.
  • Miller T. A., Witter D. J. and Belvedere S. (2003) Histone deacetylase inhibitors. J. Med. Chem. 46, 50975116.
  • Monani U. R., Coovert D. D. and Burghes A. H. (2000) Animal models of spinal muscular atrophy. Hum. Mol. Genet. 9, 24512457.
  • Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 5563.
  • Noraberg J. (2004) Organotypic brain slice cultures: an efficient and reliable method for neurotoxicological screening and mechanistic studies. Altern. Lab. Anim. 32, 329337.
  • Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A. and Klein P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36 73436 741.
  • Richon V. M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R. A. and Marks P. A. (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93, 57055708.
  • Richon V. M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R. A. and Marks P. A. (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 30033007.
  • De Ruijter A. J., Van Gennip A. H., Caron H. N., Kemp S. and Van Kuilenburg A. B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737749.
  • Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T. and Nakanishi O. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad. Sci. USA 96, 45924597.
  • Stoppini L., Buchs P. A. and Muller D. (1991) A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37, 173182.
  • Sumner C. J., Huynh T. N., Markowitz J. A. et al. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54, 647654.
  • Ungerstedt J. S., Sowa Y., Xu W. S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X. and Marks P. A. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673678.
  • Wirth B. (2000) An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat. 15, 228237.
  • Wolstencroft E. C., Mattis V., Bajer A. A., Young P. J. and Lorson C. L. (2005) A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum. Mol. Genet. 14, 11991210.